WO2023049079A3 - Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof - Google Patents

Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof Download PDF

Info

Publication number
WO2023049079A3
WO2023049079A3 PCT/US2022/044024 US2022044024W WO2023049079A3 WO 2023049079 A3 WO2023049079 A3 WO 2023049079A3 US 2022044024 W US2022044024 W US 2022044024W WO 2023049079 A3 WO2023049079 A3 WO 2023049079A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
propogating
insulin
type
Prior art date
Application number
PCT/US2022/044024
Other languages
French (fr)
Other versions
WO2023049079A2 (en
Inventor
Ngoc THAI
Jonathan POLLETT
Original Assignee
Imagine Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma Llc filed Critical Imagine Pharma Llc
Priority to IL311468A priority Critical patent/IL311468A/en
Priority to CA3231258A priority patent/CA3231258A1/en
Priority to AU2022349361A priority patent/AU2022349361A1/en
Priority to CN202280061228.4A priority patent/CN117917961A/en
Priority to KR1020247009267A priority patent/KR20240073018A/en
Publication of WO2023049079A2 publication Critical patent/WO2023049079A2/en
Publication of WO2023049079A3 publication Critical patent/WO2023049079A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein are compositions and methods for generating compositions comprising cell-based therapeutics useful for treating pancreatic disorders, including Type 1 diabetes.
PCT/US2022/044024 2021-09-22 2022-09-19 Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof WO2023049079A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL311468A IL311468A (en) 2021-09-22 2022-09-19 Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
CA3231258A CA3231258A1 (en) 2021-09-22 2022-09-19 Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
AU2022349361A AU2022349361A1 (en) 2021-09-22 2022-09-19 Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
CN202280061228.4A CN117917961A (en) 2021-09-22 2022-09-19 Compositions and methods for proliferation of insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
KR1020247009267A KR20240073018A (en) 2021-09-22 2022-09-19 Compositions and methods for propagating insulin-secreting cells and glucagon-secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163247252P 2021-09-22 2021-09-22
US63/247,252 2021-09-22
US202263337137P 2022-05-01 2022-05-01
US63/337,137 2022-05-01

Publications (2)

Publication Number Publication Date
WO2023049079A2 WO2023049079A2 (en) 2023-03-30
WO2023049079A3 true WO2023049079A3 (en) 2023-10-12

Family

ID=85721374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/044024 WO2023049079A2 (en) 2021-09-22 2022-09-19 Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof

Country Status (5)

Country Link
KR (1) KR20240073018A (en)
AU (1) AU2022349361A1 (en)
CA (1) CA3231258A1 (en)
IL (1) IL311468A (en)
WO (1) WO2023049079A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157329A1 (en) * 2001-02-15 2004-08-12 Rebecca Roubin Matrix gene expression in chondrogenesis
US20060024700A1 (en) * 2004-05-07 2006-02-02 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
US20170258853A1 (en) * 2016-03-09 2017-09-14 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US20180258401A1 (en) * 2010-03-01 2018-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US20210205371A1 (en) * 2018-06-25 2021-07-08 Imagine Pharma Llc Composition and Methods for Producing Insulin Producing Islet Cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157329A1 (en) * 2001-02-15 2004-08-12 Rebecca Roubin Matrix gene expression in chondrogenesis
US20060024700A1 (en) * 2004-05-07 2006-02-02 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
US20180258401A1 (en) * 2010-03-01 2018-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
US20170258853A1 (en) * 2016-03-09 2017-09-14 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
US20210205371A1 (en) * 2018-06-25 2021-07-08 Imagine Pharma Llc Composition and Methods for Producing Insulin Producing Islet Cells

Also Published As

Publication number Publication date
IL311468A (en) 2024-05-01
CA3231258A1 (en) 2023-03-30
KR20240073018A (en) 2024-05-24
WO2023049079A2 (en) 2023-03-30
AU2022349361A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
EP1604010A4 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
WO2006031931A3 (en) Reducing er stress in the treatment of obesity and diabetes
PH12021550442A1 (en) Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
MXPA02012272A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv.
MX2013005095A (en) Pharmaceutical composition, methods for treating and uses thereof.
NZ584848A (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
MX2021004140A (en) Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof.
MX2021015511A (en) Pyrazine carbamates and their use as glun2b receptor modulators.
MXPA05006350A (en) Culture medium composition, culture method, and myoblasts obtained, and their uses.
EA201170917A1 (en) The gene encoding human mutant glucinokinase, encoded by the enzyme, recombinant vectors and hosts, pharmaceutical compositions and their application, methods of healing.
Bachier et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed/refractory (r/r) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: Transcend NHL 001, Outreach, and PILOT
WO2023150493A3 (en) Cell therapy for diabetes
MX2009007723A (en) Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes.
Burcelin et al. Encapsulated, Genetically Engineered Cells, Secreting Glucagon‐like Peptide‐1 for the Treatment of Non‐insulin‐dependent Diabetes Mellitus
WO2023049079A3 (en) Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
ATE394118T1 (en) DIPEPTIDYL PEPTIDASE IV INHIBITORS TO REDUCE CHRONIC WEIGHT GAIN
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
ZA200703992B (en) 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
WO2019027299A3 (en) Pharmaceutical composition for preventing or treating vascular disorders including mesenchymal stem cell expressing hepatocyte growth factor as active ingredient
BR112022008201A2 (en) SURFACE PROTEIN DEGRADATION USING B-SPECIFIC BINDING AGENT
HK1097455A1 (en) Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis
ATE311466T1 (en) HUMAN PANCREAS CELL LINES: DEVELOPMENTS AND APPLICATIONS
Bara et al. Insulin-secreting L-cells for the treatment of insulin-dependent diabetes
Kelly et al. Mitochondrial gene expression changes in cultured human skin cells following simulated sunlight irradiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22873465

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2022349361

Country of ref document: AU

Ref document number: AU2022349361

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2022349361

Country of ref document: AU

Date of ref document: 20220919

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3231258

Country of ref document: CA

Ref document number: 808806

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202280061228.4

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024004061

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 311468

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2022873465

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022873465

Country of ref document: EP

Effective date: 20240422

ENP Entry into the national phase

Ref document number: 112024004061

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240229